BRAF and melanoma: Targeting of the IGF1R pathway exerts potent anticancer effects [26, 27] and combined inhibition of MAPK, PI3K, and IGF1R successfully inhibited melanoma growth and overcame resistance of melanoma cells harboring BRAF and PTEN mutations [28].